QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: Talimogene Laherparepvec, Oncolytic HSV-1 and Product Pharmacovigilance

Test your understanding of the concepts covered by Talimogene Laherparepvec: Oncolytic HSV-1, Melanoma and Product Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which statement best reflects the relationship between local injection and possible systemic immune effects?

Local injection guarantees that effects remain confined to the injected lesion Local oncolysis and GM-CSF expression can initiate immune responses affecting uninjected lesions or other organs Systemic effects prove that the product was administered intravenously Uninjected-lesion responses are incompatible with the product's mechanism

Question 2 of 10 Which statement best captures why handling precautions are part of product safety rather than merely operational logistics?

They preserve only the appearance of the vial They address the possibility that live viral material can expose workers, contacts or the environment They are needed only to prevent bacterial contamination of the patient They eliminate the need for clinical adverse-event reporting

Question 3 of 10 Which clinical feature should prompt evaluation beyond an assumed expected flu-like reaction?

Brief fatigue after injection Mild transient chills Persistent high fever with hypotension or focal infectious symptoms Short-lived nausea without other findings

Question 4 of 10 A vial was thawed incorrectly and the patient received an incomplete injection, with no immediate adverse reaction. How should this be handled?

Ignore it because pharmacovigilance applies only to symptomatic adverse events Treat it as a product-quality or medication-use event and link it to the clinical case where relevant Classify it automatically as confirmed viral transmission Record it only as a household-contact exposure

Question 5 of 10 Which case detail would most strengthen assessment of a suspected therapeutic-strain HSV infection?

The patient's preferred melanoma treatment in general Strain differentiation from wild-type HSV together with lesion morphology, timing and immune status The distance between the clinic and the patient's home The patient's baseline cholesterol level alone

Question 6 of 10 Which set of controls most directly reduces unintended exposure after the injection has been completed?

Occlusive dressings, appropriate disposal and education about avoiding contact with lesions and contaminated materials Increasing the injected volume and reducing follow-up Replacing intralesional injection with oral administration Removing all lesion documentation from the treatment record

Question 7 of 10 Which information is most important when assessing possible transmission to a household contact?

Only the patient's tumour stage Whether the contact had direct contact with lesions, dressings or contaminated material Only the patient's fatigue score Whether the patient previously received surgery, regardless of exposure

Question 8 of 10 A patient receiving talimogene laherparepvec and a checkpoint inhibitor develops pneumonitis. What is the most appropriate PV approach?

Attribute the event automatically to talimogene laherparepvec because it is an immunotherapy Attribute the event automatically to the checkpoint inhibitor because it is systemic Preserve exposure to both therapies and assess alternative causes and the clinical pattern Exclude the checkpoint inhibitor from the case because it was not injected into the lesion

Question 9 of 10 Which pairing best describes the two intended components of talimogene laherparepvec's antitumour activity?

Systemic antibody neutralisation and inhibition of angiogenesis Direct tumour-cell lysis and stimulation of tumour-directed immunity Radiation sensitisation and blockade of BRAF signalling Bacterial eradication and nonspecific tissue repair

Question 10 of 10 What is the most relevant pharmacological consequence of deleting ICP47 as described in the article?

Improved antigen presentation and altered viral gene expression Elimination of the need for intralesional administration Direct production of bacterial antibodies Complete prevention of viral shedding

QPPV.com

Knowledge Assessment: Talimogene Laherparepvec, Oncolytic HSV-1 and Product Pharmacovigilance

Cookie Settings